Please login to the form below

Not currently logged in
Email:
Password:

Syntaxin

This page shows the latest Syntaxin news and features for those working in and with pharma, biotech and healthcare.

Ipsen strengthens neurology efforts with Syntaxin purchase

Ipsen strengthens neurology efforts with Syntaxin purchase

Ipsen strengthens neurology efforts with Syntaxin purchase. French pharma firm also agrees research deal with Harvard. ... The drug, like Syntaxin's other investigational compounds, is a targeted secretion inhibitor (TSI).

Latest news

  • Oncology bias in pharma deals

    112. Syntaxin/Ipsen. Research and development collaboration. Botulinum toxins. 99. Novozymes Biopharma Sweden/Repligen Corp.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics